Literature DB >> 23012470

Complex oncogene dependence in microRNA-125a-induced myeloproliferative neoplasms.

Shangqin Guo1, Haitao Bai, Cynthia M Megyola, Stephanie Halene, Diane S Krause, David T Scadden, Jun Lu.   

Abstract

Deregulation of microRNA (miRNA) expression can lead to cancer initiation and progression. However, limited information exists on the function of miRNAs in cancer maintenance. We examined these issues in the case of myeloproliferative diseases and neoplasms (MPN), a collection of hematopoietic neoplasms regarded as preleukemic, thereby representing early neoplastic states. We report here that microRNA-125a (miR-125a)-induced MPN display a complex manner of oncogene dependence. Following a gain-of-function genomics screen, we overexpressed candidate miR-125a in vivo, which led to phenotypes consistent with an atypical MPN characterized by leukocytosis, monocytosis, splenomegaly, and progressive anemia. The diseased MPN state could be recapitulated in a doxycycline-inducible mouse model. Upon doxycycline withdrawal, the primary MPN phenotypes rapidly resolved after the discontinuation of miR-125a overexpression. However, reinduction of miR-125a led to complex phenotypes, with some animals rapidly developing lethal anemia with extensive damages in the spleen. Forced expression of miR-125a resulted in elevated cellular tyrosine phosphorylation and hypersensitivity toward hematopoietic cytokines. Furthermore, we demonstrate that miR-125a targets multiple protein phosphatases. Our data demonstrate that miR-125a-induced MPN is addicted to its sustained overexpression, and highlight the complex nature of oncogenic miRNA dependence in an early neoplastic state.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23012470      PMCID: PMC3478612          DOI: 10.1073/pnas.1213196109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

1.  The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells.

Authors:  M Sattler; S Verma; G Shrikhande; C H Byrne; Y B Pride; T Winkler; E A Greenfield; R Salgia; J D Griffin
Journal:  J Biol Chem       Date:  2000-08-11       Impact factor: 5.157

2.  A novel protein tyrosine phosphatase expressed in lin(lo)CD34(hi)Sca(hi) hematopoietic progenitor cells.

Authors:  J Cheng; L Daimaru; C Fennie; L A Lasky
Journal:  Blood       Date:  1996-08-15       Impact factor: 22.113

Review 3.  MicroRNAs as therapeutic targets in cancer.

Authors:  S Patrick Nana-Sinkam; Carlo M Croce
Journal:  Transl Res       Date:  2011-02-04       Impact factor: 7.012

4.  Cloning and characterization of PTP-K1, a novel nonreceptor protein tyrosine phosphatase highly expressed in bone marrow.

Authors:  K Huang; C L Sommers; A Grinberg; C A Kozak; P E Love
Journal:  Oncogene       Date:  1996-10-03       Impact factor: 9.867

5.  Cloning and characterization of fetal liver phosphatase 1, a nuclear protein tyrosine phosphatase isolated from hematopoietic stem cells.

Authors:  M Dosil; N Leibman; I R Lemischka
Journal:  Blood       Date:  1996-12-15       Impact factor: 22.113

6.  Circulating megakaryocyte progenitors in myeloproliferative disorders are hypersensitive to interleukin-3.

Authors:  S Kobayashi; M Teramura; S Hoshino; T Motoji; K Oshimi; H Mizoguchi
Journal:  Br J Haematol       Date:  1993-04       Impact factor: 6.998

7.  Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene.

Authors:  L D Shultz; P A Schweitzer; T V Rajan; T Yi; J N Ihle; R J Matthews; M L Thomas; D R Beier
Journal:  Cell       Date:  1993-07-02       Impact factor: 41.582

8.  Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene.

Authors:  H W Tsui; K A Siminovitch; L de Souza; F W Tsui
Journal:  Nat Genet       Date:  1993-06       Impact factor: 38.330

9.  Pulmonary pathology of the motheaten mouse.

Authors:  J M Ward
Journal:  Vet Pathol       Date:  1978-03       Impact factor: 2.221

10.  Polycythemia vera blood burst-forming units-erythroid are hypersensitive to interleukin-3.

Authors:  C H Dai; S B Krantz; R T Means; S T Horn; H S Gilbert
Journal:  J Clin Invest       Date:  1991-02       Impact factor: 14.808

View more
  26 in total

1.  An extensive network of TET2-targeting MicroRNAs regulates malignant hematopoiesis.

Authors:  Jijun Cheng; Shangqin Guo; Suning Chen; Stephen J Mastriano; Chaochun Liu; Ana C D'Alessio; Eriona Hysolli; Yanwen Guo; Hong Yao; Cynthia M Megyola; Dan Li; Jun Liu; Wen Pan; Christine A Roden; Xiao-Ling Zhou; Kartoosh Heydari; Jianjun Chen; In-Hyun Park; Ye Ding; Yi Zhang; Jun Lu
Journal:  Cell Rep       Date:  2013-10-10       Impact factor: 9.423

Review 2.  MicroRNAs in myeloproliferative neoplasms.

Authors:  Huichun Zhan; Christopher Cardozo; Azra Raza
Journal:  Br J Haematol       Date:  2013-02-25       Impact factor: 6.998

3.  A functional screen identifies miRs that induce radioresistance in glioblastomas.

Authors:  Patryk Moskwa; Pascal O Zinn; Young Eun Choi; Sachet A Shukla; Wojciech Fendler; Clark C Chen; Jun Lu; Todd R Golub; Anita Hjelmeland; Dipanjan Chowdhury
Journal:  Mol Cancer Res       Date:  2014-09-25       Impact factor: 5.852

4.  Downregulated miR-486-5p acts as a tumor suppressor in esophageal squamous cell carcinoma.

Authors:  Yunfeng Yi; Xiujuan Lu; Jianming Chen; Changjie Jiao; Jing Zhong; Zhiming Song; Xiaoping Yu; Baoli Lin
Journal:  Exp Ther Med       Date:  2016-10-05       Impact factor: 2.447

5.  Loss of the proteostasis factor AIRAPL causes myeloid transformation by deregulating IGF-1 signaling.

Authors:  Fernando G Osorio; Clara Soria-Valles; Olaya Santiago-Fernández; Teresa Bernal; María Mittelbrunn; Enrique Colado; Francisco Rodríguez; Elena Bonzon-Kulichenko; Jesús Vázquez; Montserrat Porta-de-la-Riva; Julián Cerón; Antonio Fueyo; Juan Li; Anthony R Green; José M P Freije; Carlos López-Otín
Journal:  Nat Med       Date:  2015-12-21       Impact factor: 53.440

6.  A simple high-throughput technology enables gain-of-function screening of human microRNAs.

Authors:  Wen-Chih Cheng; Tami J Kingsbury; Sarah J Wheelan; Curt I Civin
Journal:  Biotechniques       Date:  2013-02       Impact factor: 1.993

7.  Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations.

Authors:  Daichi Inoue; Jiro Kitaura; Katsuhiro Togami; Koutarou Nishimura; Yutaka Enomoto; Tomoyuki Uchida; Yuki Kagiyama; Kimihito Cojin Kawabata; Fumio Nakahara; Kumi Izawa; Toshihiko Oki; Akie Maehara; Masamichi Isobe; Akiho Tsuchiya; Yuka Harada; Hironori Harada; Takahiro Ochiya; Hiroyuki Aburatani; Hiroshi Kimura; Felicitas Thol; Michael Heuser; Ross L Levine; Omar Abdel-Wahab; Toshio Kitamura
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

8.  MicroRNAs in Control of Stem Cells in Normal and Malignant Hematopoiesis.

Authors:  Christine Roden; Jun Lu
Journal:  Curr Stem Cell Rep       Date:  2016-07-01

9.  Dual mechanisms by which miR-125b represses IRF4 to induce myeloid and B-cell leukemias.

Authors:  Alex Yick-Lun So; Reeshelle Sookram; Aadel A Chaudhuri; Aarathi Minisandram; David Cheng; Catherine Xie; Ee Lyn Lim; Yvette Garcia Flores; Shuai Jiang; Jocelyn Tammy Kim; Christopher Keown; Parameswaran Ramakrishnan; David Baltimore
Journal:  Blood       Date:  2014-07-08       Impact factor: 22.113

10.  Ectopic miR-125a Expression Induces Long-Term Repopulating Stem Cell Capacity in Mouse and Human Hematopoietic Progenitors.

Authors:  Edyta E Wojtowicz; Eric R Lechman; Karin G Hermans; Erwin M Schoof; Erno Wienholds; Ruth Isserlin; Peter A van Veelen; Mathilde J C Broekhuis; George M C Janssen; Aaron Trotman-Grant; Stephanie M Dobson; Gabriela Krivdova; Jantje Elzinga; James Kennedy; Olga I Gan; Ankit Sinha; Vladimir Ignatchenko; Thomas Kislinger; Bertien Dethmers-Ausema; Ellen Weersing; Mir Farshid Alemdehy; Hans W J de Looper; Gary D Bader; Martha Ritsema; Stefan J Erkeland; Leonid V Bystrykh; John E Dick; Gerald de Haan
Journal:  Cell Stem Cell       Date:  2016-07-14       Impact factor: 24.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.